Effective technology selection for improving bioavailability can accelerate the development of promising compounds and reduce the overall cost and complexity of drug development
An increasing number of active compounds in today's pipeline have unfavourable physico-chemical properties that require functional formulation to achieve adequate systemic exposure. Despite many new formulation strategies being utilised today, it is often difficult to match the right drug-delivery technology to a given molecule; this problem is exacerbated by the need to save time and valuable drug in early development.
At Kuecept, we have invested over £1 million in our state-of-the-art development facility, which consists of a broad spectrum of specialist processing equipment to allow clients to rapidly, cost effectively and material sparingly assess in a non-biased way which drug-delivery strategy is most suited for their particular API and which can fast-track entry into first-in-human clinical trials according to desired timelines and budget.
Supporting oral, parenteral and pulmonary drug development, all product concepts are mechanistically designed based on a comprehensive understanding of physiology (preclinical and human), key molecule physico-chemical properties and the target product profile (TPP).
Our enabling technologies include:
- Spray-dried dispersions (SDDs)
- Hot-melt extrusion (HME)
- Matrix microspheres (controlled and sustained release)
- Aqueous and organic nano-suspensions by wet-bead milling
- Solid nano-crystalline dispersions (SNCDs)
- API micronisation (wet and dry)
- Multi-particulates (immediate and controlled release)
- Solubilised liquids (including emulsions/ micro-emulsions, complexation (e.g. cyclodextrins), lipids and oily dispersions, liposomes, co-solvents)
- Gastro-intestinal targeting through enteric coating (capsules (size 0 to 9), mini-tablets, tablets, pellets / granules)
Our technologies and expertise can provide formulations to offer the following potential benefits:
- Improved oral bioavailability
- Reduced pharmacokinetic variability
- Formulations with lower toxicity and improved tolerability
- Rapid onset of action
- Suitability for delivery of high drug payloads
- Gastro-intestinal targeting across a variety of preclinical models (inc. rodents, dogs and non-human primates)
- Suitability across various dosage forms and routes of administration, including oral, parenteral and pulmonary